Product Description
Mupirocin, an antibiotic, is used to treat impetigo as well as other skin infections caused by bacteria. It is not effective against fungal or viral infections. (Sourced from: https://medlineplus.gov/druginfo/meds/a688004.html)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Nasal
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Helperby
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Impetigo|Surgical Wound Infection
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07142408 |
Cooper IRB Number 21-119 | P3 |
Recruiting |
Surgical Wound Infection |
2030-10-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
2024-517475-20-00 |
OP-IPTC02 | P3 |
Not yet recruiting |
Impetigo |
2026-08-10 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/20/2025 |
News Article |
Topical Antibiotic Drug Market Size to Capture USD 9.59 Billion by 2034 |
|
11/07/2025 |
News Article |
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing |
|
10/21/2025 |
News Article |
Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections |
|
05/13/2025 |
News Article |
iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization |